Cometriq Dosage
Generic name: cabozantinib s-malate 80mg; cabozantinib s-malate 20mg
Dosage form: capsules
Drug classes: Multikinase inhibitors, VEGF/VEGFR inhibitors
Medically reviewed by Drugs.com. Last updated on Feb 4, 2025.
Recommended Dosage
Do NOT substitute COMETRIQ capsules with cabozantinib tablets.
The recommended daily dose of COMETRIQ is 140 mg once daily without food until disease progression or unacceptable toxicity. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking COMETRIQ.
Swallow COMETRIQ capsules whole. Do not open COMETRIQ capsules.
Do not take a missed dose within 12 hours of the next dose.
Do not ingest foods (e.g., grapefruit, grapefruit juice) or nutritional supplements that are known to inhibit cytochrome P450 while taking COMETRIQ.
Dosage Modifications for Adverse Reactions
Withhold COMETRIQ for NCI CTCAE Grade 4 hematologic adverse reactions, Grade 3 or greater non-hematologic adverse reactions, intolerable Grade 2 adverse reactions, or osteonecrosis of the jaw.
Upon resolution/improvement of the adverse reaction (i.e., return to baseline or resolution to Grade 1), reduce the dose as follows:
- If previously receiving 140 mg daily dose, resume treatment at 100 mg daily
- If previously receiving 100 mg daily dose, resume treatment at 60 mg daily
- If previously receiving 60 mg daily dose, resume at 60 mg if tolerated, otherwise, discontinue COMETRIQ
Permanently discontinue COMETRIQ for any of the following:
- development of gastrointestinal (GI) perforation or Grade 4 fistula
- severe hemorrhage
- acute myocardial infarction or arterial or venous thromboembolic events that require medical intervention
- nephrotic syndrome
- severe hypertension that cannot be controlled with anti-hypertensive therapy or Grade 4 hypertension
- reversible posterior leukoencephalopathy syndrome
Dosage Modifications For Coadministration With Strong CYP3A4 Inhibitors
Reduce the daily COMETRIQ dose by 40 mg (for example, from 140 mg to 100 mg daily or from 100 mg to 60 mg daily). Resume the dose that was used prior to initiating the CYP3A4 inhibitor 2 to 3 days after discontinuation of the strong inhibitor.
Dosage Modifications For Coadministration With Strong CYP3A4 Inducers
Increase the daily COMETRIQ dose by 40 mg (for example, from 140 mg to 180 mg daily or from 100 mg to 140 mg daily) as tolerated. Resume the dose that was used prior to initiating the CYP3A4 inducer 2 to 3 days after discontinuation of the strong inducer. The daily dose of COMETRIQ should not exceed 180 mg.
Frequently asked questions
- What is the difference between Cabometyx and Cometriq?
- How long do you take Cabometyx for?
- What is the success rate of Cabometyx (cabozantinib)?
- Does Cabometyx (cabozantinib) cure cancer?
More about Cometriq (cabozantinib)
- Check interactions
- Compare alternatives
- Reviews (2)
- Imprints, shape & color data
- Side effects
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.